PerkinElmer
check quantity

GastroSense 750 Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV11121
601.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

GastroSense 750 is a near-infrared, fluorescently-labeled macromolecule that may be used to monitor the effects of disease or drugs on gastric motility and or gastric emptying. It may also be used as an anatomical marker for the gastrointestinal tract. 

GastroSense 750 may also be administered as part of a solid diet by applying the reconstituted solution to egg yolk. When added to a solid diet it may be easier to reconstitute the vial of GastroSense 750 with 300 µL of 1x PBS and use 25 µL per mouse. GastroSense remains localized in the GI tract. It does not appear to be absorbed into the bloodstream. 

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name GastroSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Ambient
Unit Size 1 Vial (10 doses)
Wave Length 750 nm
Resources, Events & More
  • All

Application Note

Gastric Emptying with GastroSense 750

The accurate quantitation of gastric emptying is crucial,for understanding the physiological, pathological and,pharmacological mechanisms underlying gastric motility,both clinically and in animal studies. Current methods,used for determining gastric emptying rates in small animals,are either terminal or involve radioactive tracers, incurring,high financial and time cost. We have developed a novel,near-infrared (NIR) fluorescent imaging agent, GastroSense™ 750, to monitor and quantitate gastric,emptying rates in murine models in vivo, non-invasively, and in real time. The imaging agent is,comprised of an acid-stable NIR fluorophore conjugated to a non-absorbable pharmacokinetic,modifier designed to be formulated in liquid or incorporated into a solid meal. Using female,8 week old BALB/c mice recipients, 0.25 nmol GastroSense 750 was orally gavaged in liquid,formulation (PBS) or fed in egg yolk, an experimental approach designed to detect changes in,gastric emptying. In vivo 3D fluorescent imaging and quantitation using the FMT®

PDF 1 MB

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Technical Note

GastroSense 750 (Data Sheet)

GastroSense™ 750 is a near-infrared, fluorescently-labeled macromolecule that may be used to monitor the effects of disease or drugs on gastric motility and or gastric emptying. It may also be used as an anatomical marker for the gastrointestinal tract.

PDF 82 KB
GastroSense 750 (Protocol)

GastroSense 750 fluorescent agent imaging protocol outlining procedures for preparing mice for imaging, preparing GastroSense 750 imaging agent, injection agent into mice, and imaging mice on IVIS and/or FMT imaging systems.

PDF 267 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB